Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories Dividend Announcement
• Dr. Reddy's Laboratories announced a semi annually dividend of $2.40 per ordinary share which will be made payable on 2024-08-12. Ex dividend date: 2024-07-30
• Dr. Reddy's Laboratories annual dividend for 2024 was $2.40
• Dr. Reddy's Laboratories annual dividend for 2023 was $4.88
• Dr. Reddy's Laboratories's trailing twelve-month (TTM) dividend yield is 3.35%
• Dr. Reddy's Laboratories's payout ratio for the trailing twelve months (TTM) is 12.49%
• Dr. Reddy's Laboratories's dividend growth over the last five years (2018-2023) was 26.85% year
• Dr. Reddy's Laboratories's dividend growth over the last ten years (2013-2023) was 33.86% year
Dr. Reddy's Laboratories Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-07-30 | $2.40 | semi annually | 2024-08-12 |
2023-07-28 | $2.44 | semi annually | 2023-08-11 |
2023-07-07 | $2.44 | semi annually | 2024-01-02 |
2022-08-01 | $0.33 | semi annually | 2022-08-12 |
2022-07-08 | $1.94 | semi annually | 2022-07-11 |
2021-07-30 | $0.28 | semi annually | 2021-08-11 |
2021-07-08 | $1.71 | semi annually | 2021-08-11 |
2020-07-10 | $0.27 | semi annually | 2020-08-17 |
2019-07-12 | $0.29 | semi annually | 2019-08-15 |
2018-07-13 | $1.49 | semi annually | 2018-08-09 |
2017-07-13 | $1.55 | semi annually | 2017-08-10 |
2016-07-14 | $1.49 | semi annually | 2016-08-09 |
2015-07-08 | $0.31 | semi annually | 2015-08-17 |
2014-08-01 | $0.30 | semi annually | 2014-08-15 |
2013-07-10 | $0.26 | semi annually | 2013-08-15 |
Dr. Reddy's Laboratories Dividend per year
Dr. Reddy's Laboratories Dividend growth
Dr. Reddy's Laboratories Dividend Yield
Dr. Reddy's Laboratories current trailing twelve-month (TTM) dividend yield is 3.35%. Interested in purchasing Dr. Reddy's Laboratories stock? Use our calculator to estimate your expected dividend yield:
Dr. Reddy's Laboratories Financial Ratios
Dr. Reddy's Laboratories Dividend FAQ
Other factors to consider when evaluating Dr. Reddy's Laboratories as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Dr. Reddy's Laboratories stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Dr. Reddy's Laboratories's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Dr. Reddy's Laboratories publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Dr. Reddy's Laboratories distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Dr. Reddy's Laboratories are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Dr. Reddy's Laboratories sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Dr. Reddy's Laboratories distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Dr. Reddy's Laboratories declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Dr. Reddy's Laboratories's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Dr. Reddy's Laboratories's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.